Daiichi Sankyo’s Asubio Pharma Allocates $102 Million To Research Plant
This article was originally published in PharmAsia News
Daiichi Sankyo subsidiary Asubio Pharma plans to spend $102 million to build a research facility near Kobe. Asubio planned the facility to be located near the world's fastest supercomputer expected to be available next year. The Daiichi Sankyo subsidiary already specializes in bio-based treatments for various ailments. Its facility is to be among one of 130 drug research and development facilities on Kobe's Port Island. (Click here for more - a subscription may be required
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.